1 Comment

CHAPTER 99 HAIRY-CELL LEUKEMIA

CHAPTER 99 HAIRY-CELL LEUKEMIA
Williams Hematology

CHAPTER 99 HAIRY-CELL LEUKEMIA

ALAN SAVEN

Definition and History
Etiology and Pathogenesis
Clinical Features
Laboratory Features

Blood

Marrow

Spleen and Other Sites

Cytochemistry

Electron Microscopy

Immunophenotype

Immunohistochemistry
Differential Diagnosis
Therapy, Course, and Prognosis

Therapy

Course and Prognosis
Chapter References

Hairy-cell leukemia is a rare chronic lymphoproliferative disorder of B-lymphocytes that display prominent cytoplasmic projections and that infiltrate the marrow and spleen in a characteristic way. Afflicted individuals are often middle-aged males who present with pancytopenia, splenomegaly, or recurrent serious infections. Treatment with cladribine has greatly improved the prognosis for patients with this disorder.

Acronyms and abbreviations that appear in this chapter include: CFU-E, erythroid colony-forming units; G-CSF, granulocyte colony-stimulating factor; IL-2, interleukin-2; HML-1, human mucosal lymphocyte 1; HTLV-II, human T-cell leukemia virus II; M-CSF, macrophage colony-stimulating; TRAP, tartrate-resistant acid phosphatase.

DEFINITION AND HISTORY
Hairy-cell leukemia is a B-lymphocyte neoplasm that principally involves the marrow and spleen. Reactive marrow fibrosis and blood cytopenias are frequent features. It was first recognized in 1923 by Ewald, who described the condition as leukämische reticuloendotheliose.1 In 1958, Bouroncle recognized the disorder to be a distinct clinicopathologic entity and referred to it as leukemic reticuloendothe-liosis.2 The descriptive term hairy-cell leukemia was coined by Schrek and Donnelly in 1966 to emphasize the irregular cytoplasmic projections of the abnormal mononuclear cells seen in the blood or marrow.3 Until the mid-1980s, the principal treatment modality for this disease was splenectomy, which resulted in transiently improved blood counts. During the past decade, the successful introduction of three effective systemic therapies—interferon-a, pentostatin (2′-deoxycoformycin), and cladribine (2-chlorodeoxyadenosine—has dramatically improved the prognosis of patients with this disease.
ETIOLOGY AND PATHOGENESIS
With 600 new patients being diagnosed annually, the disease hairy-cell leukemia accounts for approximately 2 percent of all adult leukemias in the United States. The disease is very rare in persons of African or Asian descent. It is predominantly a disease of middle-aged males, with a median age at presentation of 52 years. The disease has not been described in children or teenagers. There is a 4:1 male predominance, with Ashkenazi Jewish males being more frequently affected. Familial cases have been described.4,5 The possible association of human T-cell leukemia virus II (HTLV-II) infection with a rare T-cell hairy-cell leukemia variant has been disputed by some investigators.6 Prior exposure to radiation and organic solvents is more frequent among hairy-cell leukemia patients than among healthy persons.7,8 A possible etiologic role of the Epstein-Barr virus has been suggested in the development of the disease hairy-cell leukemia,9 but this has been disputed by other investigators.10 When cytogenetic analyses were performed in 30 patients with hairy-cell leukemia, chromosome 5 was involved in clonal aberrations in 12 (40 percent) patients, most commonly as trisomy 5 or pericentric inversions and interstitial deletions involving band 5q13.11
The normal function and precise site of origin in lymphocytic ontogeny of the hairy cell remains elusive, although it is generally accepted that hairy cells represent clonal expansions of mature B cells with phenotypic features of activation.12 Hairy cells have clonal immunoglobulin gene rearrangements13 and express the pan B-cell surface differentiation antigens CD19, CD20, and CD22, as well as monoclonal surface immunoglobulin.14 These immunologic markers of B-cell differentiation indicate an intermediate level of maturity of the hairy cell. Thus, cell surface markers normally lost in the terminal stages of B-cell maturation and CD20 are present on hairy cells, while early cell surface markers, such as CD10, are absent. Hairy cells express the early plasma cell marker PCA-1, consistent with the notion that they represent a cell at a stage of B-cell development analagous to a pre-plasma cell.15
Hairy cells secrete cytokines, such as tumor necrosis factor a. The cytokines produced by hairy cells may contribute to the impaired hematopoiesis seen in this disease by reducing the number of erythroid colony-forming units (CFU-E).16 Macrophage colony-stimulating factor (M-CSF) induces hairy-cell motility,17 and specific integrin receptors, avb3, have been identified that are responsible for their motile behavior.18
CLINICAL FEATURES
Patients with hairy-cell leukemia generally have the diagnostic triad of pancytopenia, splenomegaly, and circulating hairy cells. Pancytopenia occurs in 50 percent of the patients, and the remaining half usually have a combination of cytopenias. In a series of 102 patients with hairy-cell leukemia, 86 had anemia, 84 thrombocytopenia, and 78 neutropenia at the time of diagnosis.19 On initial presentation, one-quarter of patients present with fatigue and weakness, and another quarter with easy bruising from thrombocytopenia or with opportunistic infections from leukopenia. An additional 25 percent have early satiety or abdominal fullness from splenomegaly. The remaining patients present with an incidental finding of splenomegaly or abnormal blood counts on examination for an unrelated condition.20,21
Splenomegaly, which may be massive, is found in 90 percent of patients.22,23 Hepatomegaly is rarely a significant finding. Palpable lymphadenopathy is distinctly uncommon and when found is usually localized. However, with the advent of computed tomography scans, significant internal adenopathy can be demonstrated in up to one-third of patients with hairy-cell leukemia.24,25 In 3 percent of patients, the disease manifests itself as painful bony lesions, most commonly involving the proximal femur. Patients with skeletal complications tend to have higher tumor burdens, with their marrow being more diffusely infiltrated by hairy-cell leukemia. Diffuse osteoporosis, as well as focal or diffuse osteosclerosis, may occur. Lytic lesions, primarily involving the skeleton, have been reported.26
At diagnosis, up to 30 percent of hairy-cell leukemia patients will have an absolute blood neutrophil count of less than 0.5 × 109/liter. Most patients will demonstrate monocytopenia.27 These cytopenias predispose patients to infection from a wide variety of typical and opportunistic organisms. Impaired interferon production by blood mononuclear cells in hairy-cell leukemia also may enchance the risk for intracellular infections.28 Organisms encountered in febrile hairy-cell leukemia patients include Mycobacterium kansasii (accounting for 5–10 percent of mycobacterial disease in this population), Pneumocystis carinii, aspergillus, histoplasma, cryptococcus, and Toxoplasma gondii.29 During the follow-up of 137 patients with hairy-cell leukemia, 47 had culture-proved infections, 48 had clinically significant infectious episodes without positive cultures, and 48 had no infectious complications.30 Other laboratory abnormalities include liver function test abnormalities in 19 percent, azotemia in 27 percent, and hyperglobulinemia in 18 percent, which may be monoclonal.31 Hypogammaglobulinemia, unlike chronic lymphocytic leukemia, is rare. These paraproteinemias may, in part, contribute to some of the unusual manifestations experienced by some patients with hairy-cell leukemia, including cutaneous vasculitis, leukocytoclastic angiitis, erythema nodosum, and Raynaud’s phenomenon.31 Hypocholesterolemia, mainly due to a low concentration of low-density lipoprotein cholesterol, is a frequent finding in advanced hairy-cell leukemia but is resolved after successful treatment.32,33
In a series of 116 patients with hairy-cell leukemia followed for over two decades, several unusual presentations and complications were encountered, including spontaneous rupture of the spleen; massive splenomegaly from hairy-cell infiltration, with normal blood counts; spinal cord compression with paralysis; protein-losing enteropathy from infiltration of the bowel by hairy cells; and esophageal perforation with a fistulous tract.34 In rare cases, hairy-cell leukemia patients may have serous or chylous ascites, or pleural or pericardial effusions.35 The disease can involve soft tissues and has been implicated as a cause of uveitis in one case report.36
LABORATORY FEATURES
BLOOD
Hairy cells are mononuclear cells with eccentric or central nuclei.37 Nuclear morphology is variable, being round, ovoid, reniform, or convoluted. Nuclear forms tend to have a reticular chromatin pattern. Hairy cells have variable amounts of cytoplasm. This typically is blue-gray in appearance, exhibiting thin cytoplasmic projections (Fig. 99-1). Rarely, granules or broad-shaped inclusions can be seen in the cytoplasm, which correspond to the ribosomal lamellar complex seen on electron microscopy.38 More than 80 percent of patients have absolute neutropenia and monocytopenia.37,39,40 and 41

FIGURE 99-1 Blood fetus. The hairy cells are small to medium in size, have ovoid or reniform nuclei with finely clumped chromatin, and demonstrate abundant, frayed cytoplasm (×1500).

MARROW
The hairy cells in the marrow aspirate tend to have a slightly coarser reticular chromatin-staining pattern than those found in the blood. The marrow usually contains hairy-cell infiltrates, which in some patients may be patchy or difficult to discern. Marrow involvement may be diffuse or focal. The marrow may be hypocellular, with scant infiltration by hairy cells admixed with residual hematopoietic tissue.37,39 Hairy cells have monotonous round, oval, or spindle-spaced nuclei that are separated by abundant quantities of pale-staining cytoplasm in a fine fibrillar network. This separation of individual hairy-cell nuclei is characteristic and referred to as the “fried-egg” appearance (Fig. 99-2). Because of marked marrow reticulin fibrosis, the marrow is frequently difficult or impossible to aspirate (Fig. 99-3). Fibroblast infiltration and overt collagen fibrosis are generally absent. It has been shown that hairy cells can synthesize and assemble a fibronectin matrix that likely is responsible for the marrow fibrosis characteristic of the disease.42 The pale and delicate network of fibrils is usually recognizable but is often better appreciated with the periodic acid-Schiff stain. Occasionally, the marrow has dilated sinuses with extravasated erythrocytes, similar to the red blood cell lakes that are seen in the spleen.

FIGURE 99-2 Marrow biopsy. Diffuse infiltration by hairy cells with wide spaces between nuclei, a pattern often called “fried-egg” appearance (×2000).

FIGURE 99-3 Marrow biopsy showing marked increase in reticulin fibrils in patients with hairy-cell leukemia (×2500).

SPLEEN AND OTHER SITES
The spleen is usually enlarged, with a median weight of 1300 g.43 On section, the spleen has a dark-red, smooth surface. On light microscopy, the hairy cells involve the splenic red pulp. Later, the white pulp atrophies and is replaced. Red cell lakes are characteristic; these lakes are blood-filled spaces lined by hairy cells that have disrupted the normal sinus architecture.44 These blood-filled spaces are sometimes referred to as pseudosinuses.
Hepatic infiltration is both sinusoidal and portal.44 Lymph node involvement is marked by both sinusoidal and interstitial involvement.45 Bony infiltration can progress from the medullary cavity to the cortex, resulting in osteolytic lesions.46
CYTOCHEMISTRY
The hairy-cell cytoplasm usually stains strongly for tartrate-resistant acid phosphatase (TRAP). Isoenzyme 5 acid phosphatase, present in the hairy-cell cytoplasm, resists decolorization by tartrate.47,48 A TRAP stain that involves at least two cells with more than 40 granules or with numerous granules obscuring the nucleus is usually diagnostic. TRAP staining of the fetus of the buffy coat is positive in 90 percent of cases.47 Normal neutrophils and platelets also contain acid phosphatases but are not resistant to decolorization by tartrate. Weak to moderate TRAP staining may occur in other diseases, including prolymphocytic leukemia and lymphoma.49
ELECTRON MICROSCOPY
Hairy cells in hairy-cell leukemia have circumferential cytoplasmic projections. Hairy cells have a few blunt microvilli. The cells of patients with splenic lymphoma with circulating B lymphocytes have more numerous and finer projections that are polarized at one end of the cell (Fig. 99-4).50,51 and 52 Ribosomal lamella complexes can be found in the cytoplasm of hairy cells by transmission electron microscopy in 50 percent of patients.47 This cytoplasmic inclusion is a cylindrical structure composed of a central hollow space and an outer sheath of multiple parallel lamellae, with ribosomal-like granules in the interlamellar space.53 These complexes also have been described in other lymphoproliferative disorders.54

FIGURE 99-4 (A) Scanning and (B) transmission electron micrographs of blood hairy cells showing the characteristic circumferential, villiform cytoplasmic projections (×7000).

IMMUNOPHENOTYPE
Hairy cells express the pan B-cell antigens CD19, CD20, and CD22 but not CD21.13,55,56 Hairy cells have a pattern of surface marker expression that distinguishes them from the neoplastic cells of other lymphoproliferative disorders.57 Most distinctively, hairy cells express high levels of the CD11c, CD22, CD25, and CD103 surface antigens.58 The CD11c antigen, the 150-kD a chain of the 150/95 b2-integrin that ordinarily is expressed on monocytes and neutrophils,58,59 is expressed at levels 30-fold higher than those in chronic lymphocytic leukemia.60
Hairy-cell leukemia was the first B-cell lymphoproliferative disorder identified that expressed CD25, the a chain of the interleukin-2 (IL-2) receptor.61 Serum levels of soluble IL-2 receptor are elevated in hairy-cell leukemia patients and correlate with disease activity following treatment.62 CD103 (Bly-7) has the greatest sensitivity and specificity for hairy-cell leukemia. CD103 is the aE subunit of the aEb7-integrin, known as the human mucosal lymphocyte 1 (HML-1) antigen because HML-1 is primarily expressed by intraepithelial T lymphocytes. This integin is thought to be involved with the process of lymphocyte homing and adhesion.63,64 and 65
CD22 also is expressed more intensely on hairy cells than in other B-cell chronic lymphoproliferative disorders. For example, hairy cells express CD22 at 50-fold higher levels than in chronic lymphocytic leukemia.57 In 26 percent of cases there is weak expression of CD10 (the CALLA antigen), and in 5 percent of cases there is weak expression of CD5.
Multiparameter immunofluorescence analysis is especially useful in identifying hairy cells because it permits identification of cells co-expressing CD11c, CD25, or CD103 antigens, together with a pan B-cell antigen, such as CD19, CD20, or CD22. Using peripheral blood flow cytometry, 92 percent of 161 patients with hairy-cell leukemia had identifiable circulating hairy cells, in some patients representing less than 1 percent of lymphocytes.57 In contrast, a thorough morphologic evaluation of the blood from these same patients revealed hairy cells in only 80 percent.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry performed on marrow biopsy samples can aid in the diagnosis of hairy-cell leukemia and is useful for the detection of minimal residual disease following systemic therapies. Most monoclonal antibodies used to detect circulating hairy cells in the blood, including anti-CD103 antibodies, require that the marrow be processed by frozen section, since these antigens are destroyed by fixation and standard processing.67 In contrast, the CD20 antibody (L26) and another monoclonal antibody (DBA.44) can be used to stain hairy cells in routinely processed paraffin sections of the marrow.68,69 and 70 L26 staining is membranous and accentuates the ruffled, abundant cytoplasm of hairy cells, while DBA.44, an undefined antigen, stains in both a cytoplasmic granular and membranous pattern. DBA.44 is not specific for hairy-cell leukemia, since 30 percent of low-grade lymphomas also stain positively with this antibody.
DIFFERENTIAL DIAGNOSIS
The development of highly effective systemic therapy for hairy-cell leukemia makes distinguishing it from other lymphoproliferative disorders imperative (Table 99-1).

TABLE 99-1 DIFFERENTIAL DIAGNOSIS OF HAIRY-CELL LEUKEMIA

Myelofibrosis usually can be distinguished from hairy-cell leukemia by careful review of the blood and marrow specimens.
Hairy-cell leukemia variant is a unique clinicopathologic entity representing a hybrid between prolymphocytic leukemia and hairy-cell leukemia; the nucleus most closely resembles a prolymphocyte and the cytoplasm a hairy cell.71 Hairy-cell variant cells generally have higher nuclear-to-cytoplasmic ratios, more highly condensed chromatin, and more conspicuous central nucleoli than do the neoplastic cells of patients with classic hairy-cell leukemia.72 Afflicted individuals present with massive splenomegaly and are frequently in a leukemia phase. TRAP staining of hairy-cell variant cells is either negative or only weakly positive. Unlike classical hairy cells, the cells in the variant disease are usually CD25- and CD103-negative. Distinction of hairy-cell leukemia is based on nuclear morphology, the leukemia presentation, the lack of monocytopenia, the aspirable marrow, and the morphologic appearance of the cells seen in the marrow biopsy. Also, on electron microscopy, hairy-cell leukemia variant cells mostly lack ribosomal-lamellar complexes. There is also a blastic variant of hairy-cell leukemia, in which the patients have massive splenomegaly, peripheral adenopathy, and cytopenias.73 These cells stain positively with TRAP and do not express myeloperoxidase. More recently, a new entity, called hairy B-cell lymphoproliferative disorder, has been described in Japan.74 Patients with this disease have splenomegaly without lymphadenopathy and have a persistent lymphocytosis consisting of abnormal lymphocytes with long microvilli. The circulating lymphocytes are polyclonal B cells that are CD25-negative and only weakly TRAP positive.
Splenic lymphoma with circulating villous lymphocytes is a closely related disorder that can be difficult to distinguish from hairy-cell leukemia. Patients with splenic lymphoma with circulating villous lymphocytes also can have massive splenomegaly without lymphadenopathy. However, unlike hairy-cell leukemia, lymphocytosis is common.75 In this disorder, the lymphocytes have more basophilic cytoplasm, and the cytoplasmic projections tend to be polar and more subtle.76 Circulating plasmacytoid cells are frequently noted.51 TRAP staining is either negative or very weakly positive.47,77 The cells express high levels of CD11c but are frequently CD103 negative. Peripheral monocytopenia is usually absent. Sections of spleen show predominantly white pulp involvement resembling that of low-grade lymphoma.75
B-cell prolymphocytic leukemia is often confused with the prolymphocytic variant of hairy cell leukemia. Both disorders generally occur in elderly men with prominent splenomegaly. B-cell prolymphocytic leukemia lymphocytes are only focally TRAP-positive, whereas hairy cell leukemia classic and variant hairy cells are diffusely and strongly positive with TRAP staining. Other splenic lymphomas, including marginal zone lymphoma and monocytoid B-cell lymphoma involving the spleen, also need to be excluded.79,80 Although the morphologic features of these two disorders may approximate hairy cells, they are generally TRAP stain negative.81,82
Hairy-cell leukemia also should be differentiated from mast cell disease, especially when the infiltrates are composed of spindle-shaped cells. Mast cells are shown to contain metachromatic granules on Giemsa staining. The granules also test positive for chloroacetate esterase.83 On immunohistochemical analysis, the cells react with KPI (CDBP), a macrophage marker, but not L26 (CD20). Aged blood samples from patients with B-cell chronic lymphocytic leukemia may demonstrate artifactual cytoplasmic projections due to cytoplasmic distortion, but, unlike hairy cells, they are CD5 positive.84 Leukocytosis in chronic lymphocytic leukemia is more pronounced, and monocytopenia is usually absent.
THERAPY, COURSE, AND PROGNOSIS
THERAPY
INDICATIONS FOR THERAPY
Ninety percent of patients with hairy-cell leukemia require treatment at presentation or sometime during the course of their disease. Standard hematologic parameters for initiating therapy include anemia (hemoglobin < 9 g/dl), thrombocytopenia (platelet count < 50–100 × 109/liter), or neutropenia (absolute neutrophil count < 0.5–1.0 × 109/liter), especially if associated with recurrent, serious infections. Other, less common indications for initiating treatment are symptomatic splenomegaly, leukocytosis with a high proportion of hairy cells (white blood cell count > 20 × 109/liter), bulky or painful lymphadenopathy, vasculitis, and bony involvement.
TREATMENTS OF HISTORICAL INTEREST
Splenectomy Splenectomy was the first standard treatment modality employed in hairy-cell leukemia, since it rapidly reverses peripheral cytopenias. Ninety percent of patients will have improvement in at least one hematologic parameter, and 40 to 60 percent will have normalization of blood counts.85,86 The present indications for splenectomy are active or uncontrolled infections, thrombocytopenic bleeding, massive painful and/or ruptured splenomegaly, and failure to respond to chemotherapy including a purine analog.
Chlorambucil Chlorambucil at 2 to 4 mg orally daily for 6 to 9 months induces a consistent number of hematologic responses. The absolute neutrophil count, however, rarely improves with chlorambucil.89 There are brief reports of the salutory effects of protracted androgen90 and lithium administration in hairy-cell leukemia.91 These treatments are rarely used today, given availability of more effective systemic treatments.
Irradiation Lytic bone lesions, especially in the proximal femur, may be managed with low-dose irradiation, 1500 to 3000 Gy.46,92
Interferon The standard dose recommendation for interferon-a2b is 2 million units/m2 administered subcutaneously three times per week for 12 months, and for interferon-a2a is 3 million units/m2 subcutaneously given daily for 6 months and then decreased to three times per week for an additional 6 months.
The commonest side effect of interferon is a flulike syndrome consisting of fever, myalgias, and malaise. Acetaminophen often ameliorates these symptoms, and tachyphylaxis frequently develops over time. There is an unexpectedly high incidence of second neoplasms in patients after treatment of hairy-cell leukemia with interferon-a2b.99 Of 69 patients followed for a median of 91 months, 13 patients (19 percent) developed a second neoplasm; 6 were of hematopoietic origin, and 7 were adenocarcinomas. The median survival after diagnosis of the second neoplasm was only 9 months.
While interferon-a is an active agent in hairy-cell leukemia, it does not induce the same high complete response rates seen with the purine nucleoside analogs. Accordingly, it is likely that the use of interferon-a in the treatment of hairy-cell leukemia will be reserved for those patients with active infections and therefore unable to undergo purine nucleoside analog therapy, given their associated T-cell immunosuppression.29,107 It also may be useful in patients who have failed prior systemic therapy with a purine nucleoside analog.108
PENTOSTATIN (2′-DEOXYCOFORMYCIN)
The response rates of several pentostatin clinical trials are summarized in Table 99-2. The standard dose of pentostatin for patients with hairy-cell leukemia is 4 mg/m2 every other week for 3 to 6 months until maximum response is achieved.
Pentostatin-induced toxicities include fever, nausea, vomiting, photosensitivity, and keratoconjunctivitis.118,119 Severe myelosuppression may occur soon after the initiation of pentostatin therapy, especially in those patients with preexisting marrow compromise.114,120 Severe infections, including the disseminated herpes zoster, Escherichia coli, Haemophilus influenzae and pneumococcal and fungal infections were observed soon on after the initiation of pentostatin.119 Pentostatin is best avoided in those patients with active and uncontrolled infections, a poor performance status, or impaired renal function.113 Pentostatin is strongly immunosuppressive.121 During pento-statin therapy and for at least 1 year thereafter, CD4 and CD8 lymphocytes may decrease to levels below 200 cells/µl. Low doses of pentostatin are also potently immunosuppressive.29
CLADRIBINE (2-CHLORODEOXYADENOSINE)
Cladribine is the treatment of choice for hairy-cell leukemia. In one large series, 91 percent of 349 patients achieved an initial complete response and 7 percent a partial response, with an overall median duration of response follow-up at 52 months. Response rates to cladribine were independent of prior therapy, including pentostatin. Twenty-six percent of the patients relapsed at a median of 29 months, and, of 53 patients treated with a second course of cladribine at first relapse, 62 percent achieved a complete response. In one study, there was a slight excess of second neoplasms in cladribine-treated patients; in another study there was no such excess.
Fever is the principal toxic effect of cladribine therapy in hairy-cell leukemia, occurring in 42 percent of patients treated. The fever is related to the disappearance of hairy cells and appears most marked in those patients with the greatest pretreatment hairy-cell leukemia burden, manifested principally as splenomegaly. Documented infections unrelated to a peripherally inserted central catheter device used to deliver the cladribine are uncommon. Dermatomal herpes zoster is the most frequent late infection reported.125 Like pentostatin, 2-chlorodeoxyadenosine (cladribine) is also immunosuppressive.107 In one study, there was a tendency toward restoration of CD4 cells at 6 and 12 months,130 while other studies have shown more profound and long-lasting CD4 lymphocytopenia.131
Although in the Scripps Clinic study the time–to–treatment failure rate for complete responders was 16.3 percent at 4 years, there was no obvious plateau on the time–to–treatment failure curve.125 Thus, it is unclear what proportion of patients, if any, will be cured. Twenty-five to fifty percent of patients in morphologic complete remission after cladribine have minimal residual disease detected by immunohistochemical stains of marrow biopsies.132,133 Using the polymerase chain reaction and clonogenic probes derived from the immunoglobulin heavy-chain genes, all seven patients in apparent complete remission following cladribine showed detectable minimal residual disease.134
Cladribine can induce long-lasting complete responses in the vast majority of patients following only a single 7-day infusion. The response rates to cladribine have been shown in several published chemical trials. Relapse rates for complete responders are low, and patients who relapse can be successfully retreated with cladribine. The recommended dose of cladribine is 0.1 mg/kg per day by continuous intravenous infusion for 7 days. The optimum route and method of administration for cladribine remain under investigation. The successful administration of subcutaneous cladribine has been reported,135 as well as a weekly intravenous administration schema.136 These methods of drug delivery remain to be tested in large numbers of patients, and longer follow-up is needed to determine whether these methods of drug administration are equivalent to the continuous intravenous infusion method.
FLUDARABINE
Fludarabine, although rigorously evaluated in patients with chronic lymphocytic leukemia,137,138 has only been evaluated in small numbers of patients with hairy-cell leukemia (see Table 99-2). Although results have been less than dramatic than with other purine nucleoside analogs, some patients with a hariy-cell variant disease did achieve partial responses.139,140 and 141
SUPPORTIVE THERAPY
Granulocyte Colony-Stimulating Factor G-CSF abrogates the early myelosuppressive effects of interferon142 and reverses neutropenia in some hairy-cell leukemia patients. The role of G-CSF in the management of hairy-cell leukemia will likely be principally adjunctive to systemic therapy. It does have a role in the initial treatment of actively infected hairy-cell leukemia patients. Of four patients with hairy-cell leukemia treated with G-CSF at 1 to 6 µg/kg per day for 6 weeks, 3 patients had normalization of their absolute neutrophil count in 1 to 2 weeks.142 A single patient with hairy-cell leukemia and a history of cutaneous vasculitis developed acute neutrophilic dermatosis (Sweet syndrome) following the administration of G-CSF.
COURSE AND PROGNOSIS
Ten percent of patients, usually elderly males with smaller-sized spleens, normal blood counts, and a lower hairy-cell burden, may be observed for protracted intervals, since they generally do not require treatment.143 Prior to the successful application of interferon and purine nucleoside analogs in the treatment of hairy-cell leukemia, patients with hairy-cell leukemia had a median survival time of only 53 months.143 Now, with purine nucleoside analog therapy, overall survival rates in excess of 95 percent at 4 years have been reported.125 Regardless of the curative potential of purine nucleoside analog therapy, patients with hairy-cell leukemia can now anticipate long survival.
CHAPTER REFERENCES

1.
Ewald O: Die leukämische reticuloendotheliose. Dtsch Arch Klin Med 142:222, 1923.

2.
Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendothe-liosis. Blood 13:609, 1958.

3.
Schrek R, Donnelly J: Hairy cells in blood lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood 27:199, 1966.

4.
Wylis RF, Greene MH, Palretke M, et al: Hairy cell leukemia in three siblings: An apparent HLA-linked disease. Cancer 49:538, 1982.

5.
Egli FL, Koller B, Furrer J: Hairy cell leukemia and glucose-6-phosphatase dehydrogenase deficiency in two brothers [letter]. N Engl J Med 322:1159, 1990.

6.
Wachsman W, Golde DW, Chen IS: Hairy cell leukemia and human T cell leukemia virus. Semin Oncol 11:446, 1984.

7.
Oleske D, Golomb HM, Farber MD, et al: A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol 121:675, 1985.

8.
Stewart DJ, Keating MJ: Radiation exposure as a possible etiologic factor in hairy cell leukemia. Cancer 46:1577, 1980.

9.
Wolf BC, Martin AW, Heiman RS, et al: The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization. Am J Pathol 136:717, 1990.

10.
Chang KL, Chen YY, Weiss LM: Lack of evidence of Epstein-Barr virus in hairy cell leukemia and monocytoid B-cell lymphoma. Hum Pathol 24:58, 1993.

11.
Haglund U, Juliusson G, Stellan B, et al: Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions. Blood 83:2637, 1994.

12.
Burthem J, Zuzel M, Cawley JC: What is the nature of the hairy cell and why should we be interested? [annotation]. Br J Haematol 97:511, 1997.

13.
Korsmeyer SJ, Greene WC, Cossman J, et al: Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci USA 80:4522, 1983.

14.
Golomb HM, Davis S, Wilson C, et al: Surface immunoglobulins on hairy cells of 55 patients with hairy cell leukemia. Am J Hematol 12:397, 1982.

15.
Anderson KC, Boyd AW, Fisher DC, et al: Hairy cell leukemia: A tumor of pre-plasma cells. Blood 65:620, 1985.

16.
Lindemann A, Ludwig WD, Oster W, et al: High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood 73:880, 1989.

17.
Burthem J, Baker PK, Hunt JA, et al: The function of c-fms in hairy-cell leukemia: Macrophage colony-stimulating factor stimulates hairy-cell movement. Blood 83:1381, 1994.

18.
Burthem J, Baker PK, Cawley JC: Hairy cell interactions with extracellular matrix: Expression of specific integrin receptors and their role in the cell’s response to specific adhesive proteins. Blood 84:873, 1994.

19.
Turner A, Kjeldsberg CR: Hairy cell leukemia: A review. Medicine (Baltimore) 57:477, 1978.

20.
Flandrin G, Sigaux F, Sebahoun G, et al: Hairy cell leukemia: Clinical presentation and follow-up of 211 patients. Semin Oncol 11:458, 1984.

21.
Catovsky D: Hairy cell leukemia and prolymphocytic leukemia. Clin Haematol 6:245, 1977.

22.
Katayama I, Finkel HE: Leukemic reticuloendotheliosis: A clinicopathologic study with review of the literature. Am J Med 57:115, 1974.

23.
Golomb HM: Hairy cell leukemia, an unusual lymphoproliferative disease: A study of 24 patients. Cancer 42:946, 1978.

24.
Hakimian D, Tallman MS, Hogan DK, et al: Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia. J Clin Oncol 12:268, 1994.

25.
Mercieca J, Matutes E, Moskovic E, et al: Massive abdominal lymphadenopathy in hairy cell leukaemia: A report of 12 cases. Br J Haematol 82:547, 1992.

26.
Quesada JR, Keating MJ, Libshitz HI, et al: Bone involvement in hairy cell leukemia. Am J Med 74:228, 1983.

27.
Goyette RE: Hairy cell leukemia, in Hematology: A Comprehensive Guide to the Diagnosis and Treatment of Blood Disorders, edited by RE Goyette, p 576. PMIC, Los Angeles, 1997.

28.
Siegal FP, Shodell M, Shah K, et al: Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2′-deoxyadenosine: Implications for susceptibility to opportunistic infections. Leukemia 8:1474, 1994.

29.
Kraut EH, Neff JC, Bouroncle BA, et al: Immunosuppressive effects of pentostatin. J Clin Oncol 8:848, 1990.

30.
Golomb HM, Hadad LJ: Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 16:393, 1984.

31.
Dorsey JK, Penick GD: The association of hairy cell leukemia with unusual immunologic disorders. Arch Intern Med 142:902, 1982.

32.
Juliusson G, Vitols S, Liliemark J: Mechanisms behind hypocholesterolaemia in hairy cell leukaemia. BMJ 310:27, 1995.

33.
Juliusson G, Vitols S, Liliemark J: Disease-related hypocholesterolemia in patients with hairy cell leukemia. Cancer 76:423, 1995.

34.
Bouroncle BA: Unusual presentations and complications of hairy cell leukemia. Leukemia 1:288, 1987.

35.
Davies GE, Wiernik PH: Hairy cell leukemia with chylous ascites. JAMA 238:1541, 1977.

36.
Robinson A, Eting E, Zeidman A, et al: Ocular manifestation of hairy cell leukemia with dramatic response to 2-chloro-deoxy-adensosine. Am J Ophthalmol 121:7, 1997.

37.
Bartl R, Frisch B, Hill W, et al: Bone marrow histology in hairy cell leukemia. Am J Clin Pathol 79:531, 1983.

38.
Katayama I: Bone marrow in hairy cell leukemia. Hematol Oncol Clin North Am 2:585, 1988.

39.
Burke JS: The value of the bone-marrow biopsy in the diagnosis of hairy cell leukemia. Am J Clin Pathol 70:876, 1978.

40.
Naeim F, Jacobs AD: Bone marrow changes in patients with hairy cell leukemia treated by recombinant alpha-2 interferon. Hum Pathol 16:1200, 1985.

41.
Ratain MJ, Golomb HM, Bardawil RG, et al: Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood 69:872, 1987.

42.
Burthem J, Cawley JC: The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood 83:497, 1994.

43.
Golomb HM, Vardiman JW: Response to splenectomy in 65 patients with hairy cell leukemia: An evaluation of spleen weight and bone marrow involvement. Blood 61:349, 1983.

44.
Nanba K, Soban EJ, Bowling MC, et al: Splenic pseudosinuses and hepatic angiomatous lesions: Distinctive features of hairy cell leukemia. Am J Clin Pathol 67:415, 1977.

45.
Vardiman JW, Golomb HM: Autopsy findings in hairy cell leukemia. Semin Oncol 11:370, 1984.

46.
Lembersky BC, Ratain MJ, Golomb HM: Skeletal complications in hairy cell leukemia: Diagnosis and therapy. J Clin Oncol 6:1280, 1988.

47.
Yam LT, Janckila AJ, Li C-Y, et al: Cytochemistry of tartrate-resistant acid phosphatase: Fifteen years’ experience. Leukemia 1:285, 1987.

48.
Li CY, Yam LT, Lam KW: Studies of acid phosphatase isoenzymes in human leukocytes: Demonstration of isoenzyme specificity. J Histochem Cytochem 18:901, 1970.

49.
Drexler HG, Gaedicke G, Minowade J: Isoenzyme studies in human leukemia-lymphoma cell lines: II. Acid phosphatase. Leuk Res 9:537, 1985.

50.
Katayama I, Li CY, Yam LT: Ultrastructural characteristics of the “hairy cells” of leukemic reticuloendotheliosis. Am J Pathol 361:370, 1972.

51.
Melo JV, Robinson DS, Gregory C, et al: Splenic B cell lymphoma with “villous” lymphocytes in the peripheral blood: A disorder distinct from hairy cell leukemia. Leukemia 1:294, 1987.

52.
Catovsky D, O’Brien M, Melo JV, et al: Hairy cell leukemia variant: An intermediate disease between hairy cell leukemia and B prolymphocytic leukemia. Semin Oncol 11:362, 1984.

53.
Rosner MC, Golomb HM: Ribosome-lamella complex in hairy cell leukemia: Ultrastructure and distribution. Lab Invest 42:236, 1980.

54.
Brunning RD, Parkin J: Ribosome-lamella complexes in neoplastic hematopoietic cells. Am J Pathol 79:565, 1975.

55.
Hsu S, Yang K, Jaffe ES: Hairy cell leukemia: A B-cell neoplasm with a unique antigenic phenotype. Am J Clin Pathol 80:421, 1983.

56.
Falini B, Schwarting R, Erber W, et al: The differential diagnosis of hairy cell leukemia with a panel of monoclonal antibodies. Am J Clin Pathol 83:289, 1985.

57.
Robbins BA, Ellison DJ, Spinosa JC, et al: Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277, 1993.

58.
Visser L, Shaw A, Slupsky J, et al: Monoclonal antibodies reactive with hairy cell leukemia. Blood 74:320, 1989.

59.
Schwarting R, Stein H, Wang CY: The monoclonal antibodies alpha S-hairy cell leukemia 1 (alpha Leu-14) and alpha S-hairy cell leukemia 3 (alpha Leu-M5) allow the diagnosis of hairy cell leukemia. Blood 65:974, 1985.

60.
Hanson CA, Gribbin TE, Schnitzer B, et al: CD11c (Leu-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Blood 76:2360, 1990.

61.
de Totero D, Tazzari PL, Lauria F, et al: Phenotypic analysis of hairy cell leukemia: “Variant” cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25). Blood 82:528, 1993.

62.
Steis RG, Marcon L, Clark J, et al: Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 77:1304, 1988.

63.
Micklem KJ, Dong Y, Willis A, et al: HML-1 antigen on mucosa-associated T cells, activated cells, and hairy leukemic cells is a new integrin containing the b7 subunit. Am J Pathol 139:1297, 1991.

64.
Flenghi L, Spinozzi F, Stein H, et al: LF61: A new monoclonal antibody directed against a trimeric molecule (150 kDa, 125 kDa, 105 kDa) associated with hairy cell leukemia. Br J Haematol 76:451, 1990.

65.
Cepek KL, Parker CM, Madara JL, et al: Integrin alpha E beta F mediates adhesion of T lymphocytes to epithelial cell. J Immunol 150:3459, 1993.

66.
Linde GA, Hammarstrom L, Persson MAA, et al: Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun 42:237, 1983.

67.
Thaler J, Denz H, Dietze O, et al: Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: Changes following treatment with alpha-2-interferon and deoxycoformycin. Leuk Res 13:377, 1989.

68.
Stroup R, Sheibani K: Antigenic phenotypes of hairy cell leukemia and monocytoid B-cell lymphoma: An immunohistochemical evaluation of 66 cases. Hum Pathol 23:172, 1992.

69.
al Saati T, Caspar S, Brousset P, et al: Production of anti-B monoclonal antibodies (DBB.42, DBA.44, DNA.7, and DND.53) reactive on paraffin-embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice. Blood 74:2476, 1989.

70.
Hounieu H, Chittal SM, al Saati T, et al: Hairy cell leukemia: Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol 98:26, 1992.

71.
Sainati L, Matutes E, Mulligan S, et al: A variant form of hairy cell leukemia resistant to alpha-interferon: Clinical and phenotypic characteristics of 17 patients. Blood 76:157, 1990.

72.
Cawley JC, Burns GF, Hayhoe RGH: A chronic lymphoproliferative disorder with distinctive features: A distinct variant of hairy cell leukemia. Leuk Res 4:547, 1980.

73.
Diez-Martin JL, Li CY, Banks PM: Blastic variant of hairy cell leukemia. Am J Clin Pathol 87:576, 1987.

74.
Machii T, Yamaguchi M, Inoue R, et al: Polyclonal B-cell lymphocytosis with features resembling hairy cell leukemia-Japanese variant. Blood 89:2008, 1997.

75.
Sun T, Susin M, Brody J, et al: Splenic lymphoma with circulating villous lymphocytes: Report of seven cases and review of the literature. Am J Hematol 45:39, 1994.

76.
Hanson CA, Ward PC, Schnitzer B: A multilobular variant of hairy cell leukemia with morphologic similarities to T-cell lymphoma. Am J Surg Pathol 13:671, 1989.

77.
Yam LT, Li CY, Lam KW: Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med 284:357, 1971.

78.
Slovak ML, Weiss LM, Nathwan BN, et al: Cytogenetic studies of composite lymphomas: Monocytoid B-cell lymphoma and other B-cell non-Hodgkin’s lymphomas. Hum Pathol 24:1086, 1993.

79.
Sheibani K, Burke JS, Swartz WG, et al: Monocytoid B-cell lymphoma: Clinicopathologic study of 21 cases of a unique type of low-grade lymphoma. Cancer 62:1531, 1988.

80.
Shin SS, Sahibani K: Monocytoid B-cell lymphoma. Am J Clin Pathol 99:421, 1973.

81.
Saven A, Piro LD: Hairy cell leukemia, in Hematology: Basic Principles and Practice, edited by Hoffman R, Benz EJ, Shattil SJ, Furie B, et al, p 1322. Churchill Livingstone, New York, 1995.

82.
Traweek ST, Sheiban K: Monocytoid B-cell lymphoma: The biologic and clinical implications of peripheral blood involvement. Am J Clin Pathol 97:591, 1992.

83.
Burke JS, Rappaport H: The differential diagnosis of hairy cell leukemia in bone marrow and spleen. Semin Oncol 11:334, 1984.

84.
Keating MJ: Chronic lymphoproliferative disorders: Chronic lymphocytic leukemia and hairy cell leukemia. Curr Opin Oncol 5:35, 1993.

85.
Mintz U, Golomb HM: Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res 39:2366, 1979.

86.
Jansen J, Hermans J: Splenectomy in hairy cell leukemia: A retrospective multicenter analysis. Cancer 47:2066, 1981.

87.
Lewis SM, Catovsky D, Hows JM, et al: Splenic red cell pooling in hairy cell leukemia. Br J Haematol 35:351, 1977.

88.
Golde DW: Therapy of hairy-cell leukemia. N Engl J Med 307:495, 1982.

89.
Golomb HM: Progress report on chlorambucil therapy in postsplenectomy patients with progressive hairy cell leukemia. Blood 57:464, 1981.

90.
Lusch CJ, Ramsey HE, Katayama I: Leukemic reticuloendotheliosis: Report of a case with peripheral blood remission on androgen therapy. Cancer 41:1964, 1978.

91.
Blum SF: Lithium in hairy cell leukemia. N Engl J Med 303:464, 1983.

92.
Arkel YS, Lake-Lewin D, Sarapoulous AA, et al: Bone lesions in hairy cell leukemia. Cancer 53:2401, 1984.

93.
Quesada JR, Reuben J, Manning JT, et al: Alpha-interferon for induction of remission in hairy cell leukemia. N Engl J Med 310:15, 1984.

94.
Golomb HM, Jacobs A, Fefer A, et al: Alpha-2 interferon therapy of hairy cell leukemia: A multicenter study of 64 patients. J Clin Oncol 4:900, 1986.

95.
Golomb HM, Ratain MJ, Fefer A, et al: Randomized study of the duration of treatment with interferon alfa-2b in patients with hairy cell leukemia. J Natl Cancer Inst 80:369, 1988.

96.
Berman E, Heller G, Kempin S, et al: Incidence of response and long-term follow-up in patients with hairy cell leukemia with recombinant alpha-2a. Blood 75:839, 1990.

97.
Quesada JR, Hersh EM, Manning J, et al: Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 68:493, 1986.

98.
Von Wussow P, Pralle H, Hochkeppel H, et al: Effective natural interferon-a therapy in recombinant interferon-a-resistant patients with hairy cell leukemia. Blood 78:38, 1991.

99.
Ratain MJ, Golomb HM, Vardiman JW, et al: Relapse after interferon alpha-2b therapy for hairy-cell leukemia: Analysis of diagnostic variables. J Clin Oncol 6:1714, 1988.

100.
Ratain MJ, Golomb HM, Vardiman JW, et al: Interferon alpha-2b therapy for hairy cell leukemia in 69 patients: A 6-year update [abstr]. Blood 74:76, 1989.

101.
Kampmeier P, Spielberger R, Dickstein J, et al: Increased incidence of second neoplasms in patients treated with interferon a-2b for hairy cell leukemia: A clinicopathologic assessment. Blood 83:2931, 1994.

102.
Ruco LP, Procapio A, Maccallini V, et al: Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 61:1132, 1983.

103.
Lee SH, Kelley S, Chin H, et al: Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes. Cancer Res 42:1312, 1982.

104.
Lieberman D, Voloch Z, Aviv H, et al: Effects of interferon on hemoglobin synthesis and leukemia virus production in Friend cells. Mol Biol Rep 1:447, 1974.

105.
Taylor-Papadimitriou J: Effects of interferons on cell growth and function, in Interferon 1980, vol 2, edited by I Gresser, p 13. Academic Press, New York, 1980.

106.
Jansen JH, Van der Harst D, Wientjens G-JHM, et al: Induction of CD11a/leukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer cell cytotoxicity. Blood 80:478, 1992.

107.
Juliusson G, Lenkei R, Liliemark J: Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 83:3672, 1994.

108.
Seymour JF, Estey EH, Keating MJ, et al: Response to interferon-a in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 9:929, 1995.

109.
Giblett ER, Anderson JE, Cohen F, et al: Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067, 1972.

110.
Cohen A, Hirshhorn R, Horowitz SD, et al: Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 75:472, 1978.

111.
Carson DA, Wasson DB, Kaye J, et al: Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 77:6865, 1980.

112.
Spiers ASD, Parekh SJ: Pentostatin (2′-deoxycoformycin, DCF) is active in hairy cell leukemia (hairy cell leukemia) [abstr]. Blood 62:208, 1983.

113.
Spiers ASD, Moore D, Cassileth PA, et al: Remissions in hairy cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 316:825, 1987.

114.
Cassileth PA, Cheuvant B, Spiers ASD, et al: Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 9:243, 1991.

115.
Ho AD, Thaler J, Stryckmans P, et al: Pentostatin in resistant chronic lymphocytic leukemia: A phase II trial of the European organization for research and treatment of cancer. Proc Am Soc Clin Oncol 9:206, 1990.

116.
Grever M, Kopecky K, Foucar K, et al: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An Iintergroup study. J Clin Oncol 13:974, 1995.

117.
Kraut EH, Grever MR, Bouroncle BA: Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 84:4061, 1994.

118.
Spiers ASD, Parekh SJ, Bishop MB: Hairy-cell leukemia: Induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 2:1336, 1984.

119.
Johnston JB, Glazer RI, Pugh L, et al: The treatment of hairy-cell leukemia with 2′-deoxycoformycin. Br J Haematol 63:525, 1986.

120.
Ho AD, Thaler J, Stryckmans P, et al: Pentostatin in refractory chronic lymphocytic leukemia: A phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 82:1416, 1990.

121.
Urba WJ, Baseler MW, Kopp WC, et al: Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73:38, 1989.

122.
Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117, 1990.

123.
Juliusson G, Liliemark J: Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): Relation to opportunistic infections. Blood 79:888, 1992.

124.
Estey EM, Kurzrock R, Kantarjian HM, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79:882, 1992.

125.
Saven A, Burian C, Koziol JA, et al: Long-term follow-up of patients with hairy cell leukemia following cladribine treatment. Blood 92:1918, 1998.

126.
Saven A, Piro LD: Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann Intern Med 119:278, 1993.

127.
Kurzrock R, Strom SS, Estey E, et al: Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 15:1803, 1997.

128.
Tallman MS, Hakimian D, Rademaker AW, et al: Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience. Blood 88:1954, 1996.

129.
Hoffman MA, Janson D, Rose E, et al: Treatment of hairy cell leukemia with cladribine: Response, toxicity and long-term follow-up. J Clin Oncol 15:1138, 1997.

130.
Carrera CJ, Piro LD, Saven A, et al: Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia [abstr]. Blood 76(suppl 1):260a, 1990.

131.
Seymour J, Kurzrock R, Freireich EJ, et al: 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906, 1994.

132.
Hakimian D, Tallman MS, Kiley C, et al: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82:1798, 1993.

133.
Ellison DJ, Sharpe RW, Robbins BA, et al: Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 84:4310, 1994.

134.
Filleul B, Delannoy A, Ferrant A, et al: A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell patients in complete remission. Leukemia 8:1153, 1994.

135.
Juliusson G, Heldal D, Hippe E, et al: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13:989, 1995.

136.
Lauria F, Bocchia M, Marotta G, et al: Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: A new treatment schedule effective and safer in preventing infectious complications [letter]. Blood 89:1838, 1998.

137.
Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19, 1989.

138.
Keating MJ, Kantarjian H, O’Brien S, et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44, 1991.

139.
Kantarjian HM, Redman J, Keating MJ: Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 17(suppl 8):66, 1990.

140.
Kantarjian HM, Schachner J, Keating MJ: Fludarabine therapy in hairy cell leukemia. Cancer 67:1291, 1991.

141.
Kraut E, Chun H: Fludarabine phosphate in refractory hairy cell leukemia. Am J Hematol 37:59, 1991.

142.
Glaspy JA, Baldwin GC, Robertson PA, et al: Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 109:789, 1988.

143.
Golomb HM, Catovsky D, Golde DW: Hairy cell leukemia: A clinical review of 71 cases. Ann Intern Med 89:677, 1978.

144.
Quesada JR, Gutterman J, Hersh EM: Treatment of hairy cell leukemia with alpha interferons. Cancer 57:1678, 1986.

145.
Foon KA, Maluish AE, Abrams PG, et al: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: Therapeutic and immunologic results. Am J Med 80:351, 1986.

146.
Rai K, Mick R, Ozer H, et al: Alpha-interferon therapy in untreated active hairy cell leukemia: A Cancer and Leukemia Group B (CALGB) study [abstr]. Proc Am Soc Clin Oncol 6:159, 1987.

147.
Golomb H, Fefer A, Golde D, et al: Update of a multi-institutional study of 195 patients (pts) with hairy cell leukemia treated with interferon alfa-2b (IFN) [abstr]. Proc Am Soc Clin Oncol 6:215, 1990.

148.
Grever M, Kopecky K, Foucar MK, et al: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An Intergroup study. J Clin Oncol 13:974, 1995.

149.
Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 7:168, 1989.

150.
Grem J, King S, Cheson B, et al: Pentostatin in hairy cell leukemia: Treatment by the special exception mechanism. J Natl Cancer Inst 81:448, 1989.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

Advertisements

One comment on “CHAPTER 99 HAIRY-CELL LEUKEMIA

  1. nice work you’ve done. Good content and i like spending 15 minutes a day watchin all the new posts. Good job, tnx !!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: